Floatz logo

Gleevec/Glivec

Advanced Melanoma

Abramson Cancer Center at Penn MedicinePhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

35 Active assets in the Advanced Melanoma cohort.

Asset / SponsorPhaseRating
PROPRANOLOL
Sarah Weiss
Phase 2/3B
Bcd-263
Biocad
Phase 3B
Iparomlimab
Hebei Medical University Fourth Hospital
Phase 4B
Tuvonralimab
Hebei Medical University Fourth Hospital
Phase 4B
Autogene Cevumeran
Genentech, Inc.
Phase 2B

View all 50 →

Same molecule, other indications

Gleevec/Glivec is also rated in:

myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
52 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →